Reduction in disease progression with nintedanib in the INPULSIS™ trials
V. Cottin, H. Taniguchi, H. R. Collard, L. Richeldi, S. Stowasser, I. Tschoepe, R. Schlenker-Herceg, G. Raghu (Lyon, Reims, France; Aichi, Japan; San Francisco, Ridgefield, Seattle, United States Of America; Southampton, United Kingdom; Ingelheim am Rhein, Germany)
Source: International Congress 2014 – Clinical trials in IPF
Session: Clinical trials in IPF
Session type: Oral Presentation
Number: 1906
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Cottin, H. Taniguchi, H. R. Collard, L. Richeldi, S. Stowasser, I. Tschoepe, R. Schlenker-Herceg, G. Raghu (Lyon, Reims, France; Aichi, Japan; San Francisco, Ridgefield, Seattle, United States Of America; Southampton, United Kingdom; Ingelheim am Rhein, Germany). Reduction in disease progression with nintedanib in the INPULSIS™ trials. Eur Respir J 2014; 44: Suppl. 58, 1906
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: